As the Minister of Health had announced, and after evaluation by the National Medicines Safety Agency, hexahydrocannabinol (HHC) and two of its derivatives, HHC-acetate (HHCO) and hexahydroxycannabiphorol (HHCP) will be included on the list of narcotic products from Tuesday, June 13, 2023.
Their production, marketing and consumption will therefore be prohibited on the same date in France, joining many countries in Europe which already prohibit it.
As promised, HHC has been assessed and is now classified as narcotic by the@ansm. From tomorrow, the consumption and sale of HHC will be prohibited. my ministry @Sante_Gouv is mobilized to protect the health of French people and fight against addictions.
— Francois Braun (@FrcsBraun) June 12, 2023
HHC, HHCO, HHCP: what are we talking about?
HHC is obtained by a chemical process of hydrogenation of CBD. The synthetic molecule, which exists in very low doses and only in seeds in the natural environment, is said to produce effects psychotropic similar to those experienced when consuming THC. Sold especially on the internet and in CBD shops, HHC comes in the form of a distillate-like extract that can then be inserted into oils, resins, vapes or food derivatives, or sprayed on hemp flowers. . The HHC concentration of products sold on the market is variable and can reach up to 99%, depending on the forms and brands.
According to the ANSM, the monitoring carried out by the national addictovigilance network indicates that the consumption of HHC is currently increasing in France, sometimes without the knowledge of users who think they are consuming another product, such as CBD.
According to various feedback, the HHC had taken a clear share in the turnover of CBD shops and online sales, demonstrating in particular the appeal of a “legally” sold product. Will manufacturers attack this ranking as it was done for CBD? On to the next episode.